Pharmedic (PMC) Ordered Nationwide Eye Drop Recall Over Quality Violations

Overview

Pharmedic (PMC), a long-standing Vietnamese pharmaceutical company, has been ordered by the Drug Administration of Vietnam (DAV) to recall a batch of sodium chloride 0.9% eye drops nationwide due to quality non-compliance. The recall follows a previous fine of VND 70 million for a drug quality violation in 2026. The company generates approximately VND 500 billion in annual revenue and is listed on HOSE.

Key Facts

• The recalled batch is sodium chloride 0.9% eye drops, registration number 893100060724, batch 10370725, manufactured on 14/7/2025, expiry 14/1/2028.
• The violation is for clarity index non-compliance, classified as level 3 (moderate risk).
• Recall must be completed within 30 days from 11/5/2026.
• Pharmedic was previously fined VND 70 million on 19/1/2026 for producing Diclofen batch 0040724 with quality level 2 violation.
• The company reported annual revenue of about VND 500 billion.
• PMC closed at VND 138,500 on 15/5/2026, down 0.72% with low volume of 1,600 shares.
• Pharmedic is one of Vietnam’s oldest pharmaceutical firms, founded in 1981 as PHARIMEX.

What Happened

The Drug Administration of Vietnam issued a decision to recall a batch of sodium chloride 0.9% eye drops produced by Pharmedic (PMC) due to failure in clarity quality standards (level 3 violation). The recall applies nationwide, requiring Pharmedic to cease distribution, quarantine remaining stock, and coordinate with wholesalers and healthcare facilities to retrieve the batch. The company must complete the recall within 30 days from 11/5/2026 and bear all costs, including compensation.

This is the second quality-related incident for Pharmedic in recent years. In January 2026, the DAV fined the company VND 70 million for producing a substandard batch of Diclofen (level 2 violation) and ordered its destruction. During the 2026 annual general meeting, a shareholder questioned why the earlier fine was not disclosed in reports; management described it as a minor supply chain issue not requiring disclosure.

Market Context

PMC shares closed at VND 138,500 on 15/5/2026, down 0.72% with extremely low volume of 1,600 shares, indicating limited market reaction to the recall news. The stock trades on HOSE. The pharmaceutical sector in Vietnam has seen increased regulatory scrutiny on drug quality, with several companies facing recalls and fines. Pharmedic’s revenue of ~VND 500 billion places it as a mid-tier player, below top firms like DHG Pharma and Traphaco.

Strategic Significance

The repeated quality issues suggest potential weaknesses in Pharmedic’s manufacturing quality control and supply chain management. While the financial impact of the recall is likely limited (a single batch), the reputational damage could affect customer trust and future contract wins, especially with healthcare institutions. The company’s ability to address root causes and prevent recurrence will be critical for maintaining its market position. Investors should monitor whether this leads to increased regulatory oversight or stricter enforcement.

What to Watch

• Pharmedic’s official statement on root cause analysis and corrective actions.
• Any further regulatory actions or fines from the DAV.
• Q2 2026 earnings report for potential impact on revenue or provisions.
• Changes in procurement contracts with hospitals or distributors.
• Share price and trading volume reaction over the next few weeks.